Laychiluh Mekonnen - Search Results

Year	Number of Results
2015	2
2016	1
2017	2
2019	2
2021	1
2022	1
2023	4
2024	0

1

Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies.

Safaroghli-Azar A, Emadi F, Lenjisa J, Mekonnen L, Wang S. Safaroghli-Azar A, et al. Among authors: mekonnen l. Drug Discov Today. 2023 May;28(5):103525. doi: 10.1016/j.drudis.2023.103525. Epub 2023 Mar 11. Drug Discov Today. 2023. PMID: 36907320 Review.

2

Targeting CDK9: a promising therapeutic opportunity in prostate cancer.

Rahaman MH, Kumarasiri M, Mekonnen LB, Yu M, Diab S, Albrecht H, Milne RW, Wang S. Rahaman MH, et al. Among authors: mekonnen lb. Endocr Relat Cancer. 2016 Dec;23(12):T211-T226. doi: 10.1530/ERC-16-0299. Epub 2016 Aug 31. Endocr Relat Cancer. 2016. PMID: 27582311 Review.

3

Discovery of CDK5 Inhibitors through Structure-Guided Approach.

Khair NZ, Lenjisa JL, Tadesse S, Kumarasiri M, Basnet SKC, Mekonnen LB, Li M, Diab S, Sykes MJ, Albrecht H, Milne R, Wang S. Khair NZ, et al. Among authors: mekonnen lb. ACS Med Chem Lett. 2019 Mar 20;10(5):786-791. doi: 10.1021/acsmedchemlett.9b00029. eCollection 2019 May 9. ACS Med Chem Lett. 2019. PMID: 31098000 Free PMC article.

4

2-Anilino-4-(1-methyl-1H-pyrazol-4-yl)pyrimidine-derived CDK2 inhibitors as anticancer agents: Design, synthesis & evaluation.

Fanta BS, Mekonnen L, Basnet SKC, Teo T, Lenjisa J, Khair NZ, Kou L, Tadesse S, Sykes MJ, Yu M, Wang S. Fanta BS, et al. Among authors: mekonnen l. Bioorg Med Chem. 2023 Feb 15;80:117158. doi: 10.1016/j.bmc.2023.117158. Epub 2023 Jan 11. Bioorg Med Chem. 2023. PMID: 36706608

5

A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors.

Tadesse S, Zhu G, Mekonnen LB, Lenjisa JL, Yu M, Brown MP, Wang S. Tadesse S, et al. Among authors: mekonnen lb. Future Med Chem. 2017 Sep;9(13):1495-1506. doi: 10.4155/fmc-2017-0076. Epub 2017 Aug 10. Future Med Chem. 2017. PMID: 28795589

6

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.

Yu M, Teo T, Yang Y, Li M, Long Y, Philip S, Noll B, Heinemann GK, Diab S, Eldi P, Mekonnen L, Anshabo AT, Rahaman MH, Milne R, Hayball JD, Wang S. Yu M, et al. Among authors: mekonnen l. Eur J Med Chem. 2021 Mar 15;214:113248. doi: 10.1016/j.ejmech.2021.113248. Epub 2021 Feb 3. Eur J Med Chem. 2021. PMID: 33571827

7

Discovery of Potent Inhibitors of Cyclin-Dependent Kinases 7 and 9: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.

Chen R, Hassankhani R, Long Y, Basnet SKC, Teo T, Yang Y, Mekonnen L, Yu M, Wang S. Chen R, et al. Among authors: mekonnen l. ChemMedChem. 2023 Feb 1;18(3):e202200582. doi: 10.1002/cmdc.202200582. Epub 2022 Nov 27. ChemMedChem. 2023. PMID: 36400715

8

Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation.

Fanta BS, Lenjisa J, Teo T, Kou L, Mekonnen L, Yang Y, Basnet SKC, Hassankhani R, Sykes MJ, Yu M, Wang S. Fanta BS, et al. Among authors: mekonnen l. Molecules. 2023 Mar 25;28(7):2951. doi: 10.3390/molecules28072951. Molecules. 2023. PMID: 37049714 Free PMC article.

9

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.

Tadesse S, Yu M, Mekonnen LB, Lam F, Islam S, Tomusange K, Rahaman MH, Noll B, Basnet SK, Teo T, Albrecht H, Milne R, Wang S. Tadesse S, et al. Among authors: mekonnen lb. J Med Chem. 2017 Mar 9;60(5):1892-1915. doi: 10.1021/acs.jmedchem.6b01670. Epub 2017 Feb 16. J Med Chem. 2017. PMID: 28156111 Free article.

10

Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.

Abdelaziz AM, Diab S, Islam S, Basnet SKC, Noll B, Li P, Mekonnen LB, Lu J, Albrecht H, Milne RW, Gerber C, Yu M, Wang S. Abdelaziz AM, et al. Among authors: mekonnen lb. Med Chem. 2019;15(6):602-623. doi: 10.2174/1573406415666181219111511. Med Chem. 2019. PMID: 30569866

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

12 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year